Veronique D
- Biogen (BIIB) shares rose 2.1% in Monday’s premarket trading after JPMorgan upgraded the stock to overweight from neutral, citing an increasingly attractive pipeline of catalysts expected in 2027.
- The brokerage set a PT of $300, which implies a 33% increase from last close.